

BRD4 Targeted Therapies Market Opportunity, Technology Platform, Development Trends & Clinical Trials Insights 2026

<https://marketpublishers.com/r/BDC6EBCA146CEN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,000.00 (Single User License)

ID: BDC6EBCA146CEN

Abstracts

BRD4 Targeted Therapies Market Opportunity, Technology Platform, Development Trends & Clinical Trials Insights 2026 Report Findings & Highlights:

First BRD4 Targeted Approval Expected By 2030

Emergence Of BRD4 As A Lead BET Target

Comprehensive Analysis of Novel Therapeutic Strategies Targeting BRD4

BRD4 Targeting Therapies Clinical Trials Insight: > 20 Therapies In Trials

Global BRD4 Targeting Therapies Clinical Trials By Company, Indication & Phase

Technology and Drug Development Platforms Driving Next Generation BRD4 Therapies

Competitive Landscape

Need For BRD4 Targeted Therapies & Why This Report?

BRD4 targeted therapies is one of the most rapidly evolving, most exciting and promising sub field within both epigenetic drug development and precision oncology landscape. As the crucial master transcriptional regulator controlling tumor growth,

proliferation, metastasis, immunity, resistance to treatment, the bromodomain containing protein 4 (BRD4) has become an incredibly exciting target in the treatment of multiple cancer types. Different from existing cancer drug targets modulating specific signaling pathways, BRD4 as a transcriptional hub plays a pivotal role to orchestrate tumor's key oncogenic transcriptional program including MYC driven gene expression and super enhancer function.

The path to the development of BRD4 targeted therapies has evolved from first generation pan BET inhibitors to increasingly refined and selective strategies for increased efficacy and longevity, targeting bromodomains with enhanced precision to induce gene silencing through novel mechanisms including selective BRD4 inhibitors, bromodomain specific molecules, covalent and allosteric BRD4 inhibitors, targeted protein degraders and combination treatments.

This report delivers a thorough analysis of the evolving landscape of BRD4 targeted therapies including scientific rationales, drug development approaches, clinical updates, novel technologies, competitive landscape and the potential commercial future. It provides insights for investors and pharmaceutical companies in identifying key market opportunities, novel technologies, competitive landscape and opportunities for investment, collaboration and portfolio development for the emerging BRD4 targeting therapy market.

Clinical Trials Insight Included In Report

The clinical development plays an important role in evaluating the future prospects of BRD4 targeted treatments. There is no approved treatment directed against BRD4 so far; however, a number of candidates have completed or are ongoing in clinical research for BRD4 targeted therapies in various hematological malignancies and solid tumors. The report analyzes the current pipeline of BRD4 targeted treatment candidates, as well as those in early and advanced stages of clinical research, that target BRD4 and BET inhibitors in diseases such as acute myeloid leukemia, myelofibrosis, lymphomas, prostate cancer, pediatric cancers, and solid tumors.

This report includes extensive research on current clinical trials and studies targeting BRD4, which involve a wide array of indications, patient populations, clinical phase, and treatments. The information provided involves an analysis of BRD4 monotherapy, as well as combination approach, focusing on the use of BRD4 targeted drugs in combination with epigenetic drugs, apoptosis inducers, kinase inhibitors, DNA repair treatment, and immunotherapy. Furthermore, information about the organizations

carrying out the research, such as pharmaceutical companies, biopharmaceutical organizations, and academia, is included in this report, giving a clear picture to the readers regarding the sponsors of BRD4 targeted therapies.

Major Companies Active In R&D Of BRD4 Targeted Therapies

In terms of therapeutic landscape, BRD4 involves a wide range of pharmaceutical companies and biotech firms, as well as research organizations involved in the development of BRD4 targeting drugs in various therapeutic fields. The initial efforts of drug development were mainly represented by companies working on BET inhibitors, as evidenced by development of pelabresib, PLX2853, BMS-986158 and ABBV-075 programs, which contributed to clinical knowledge of BRD4 inhibition in hematology and oncology. These early programs laid the groundwork for the clinical relevance of BRD4 and paved the way for new developments in selective and next generation approaches.

The current competitive landscape consists of companies that develop novel BRD4 targeting strategies, including selective BRD4 inhibitors, degradation of BRD4 protein, and combination therapy. Some of these biotech firms include Halda Therapeutics, DeepCure, Model Medicines, and others. In addition, academic institutions provide the foundation of the competitive landscape through the discovery of novel mechanisms of regulation and treatment opportunities for BRD4. It should be noted that increasing number of industry participants, collaborations, and investments of pharmaceutical companies into drug development of BRD4 show commercial potential of this approach to drug development.

Technology Platforms, Collaborations & Agreements

Technological advancements have resulted in the exploration of non-traditional treatment methods that utilize platforms developed by the companies to modulate the targets in a more selective and sustainable manner. Innovative treatment modalities include protein degradation, such as PROTAC and molecular glues, AI enabled drug discovery, RNA silencing, and precision delivery of the compounds. For instance, the RIPTAC™ technology of Halda Therapeutics is an innovative platform targeting the disruption of essential cancerous proteins in tumor cells to develop the product called HLD-0915 for treating prostate cancer. These platforms seek to overcome the challenges of traditional BET inhibitors and develop next generation treatments based on BRD4.

Collaborations involving biotech companies, pharmaceuticals, and academic research

institutions have continued to boost innovation in this sphere. Collaborations aimed at developing protein degradation, AI enabled drug discovery, biomarker identification, and precise delivery technologies broaden the range of potential uses for BRD4 based therapies. The report evaluates key technological developments, partnerships, licenses, and platform approaches that will shape the future of BRD4 targeting therapy development.

Report Indicating Future Direction Of BRD4 Targeted Therapies

Precision, new modes of action, and expanded applications represent likely themes for BRD4 targeting therapies in the future. Next generation inhibitors that would target either BRD4 or specific bromodomains may allow opening of additional therapeutic windows, whereas degradation technologies may offer greater ability to silence transcription programs regulated by BRD4. Combination technologies may also play a major role in the growth of BRD4 targeting therapies, which may allow complementing conventional anti-cancer drugs and overcoming resistance mechanisms.

In addition to oncology, a growing understanding of BRD4 biology may open up new horizons for BRD4 therapies in inflammatory diseases, cardiovascular disorders, infectious diseases, and other indications that feature abnormal transcription regulation. The convergence of biomarker driven patient selection, advanced drug delivery technologies, and novel therapeutic platforms will define the future direction of BRD4 research and development. The report offers a comprehensive assessment of these opportunities, providing perspectives on scientific advancement, commercial potential, and future positioning of therapies targeting BRD4.

Contents

1. RESEARCH METHODOLOGY

2. INTRODUCTION TO BET FAMILY & BRD4 TARGETING

- 2.1 Overview Of Epigenetic Drug Targets
- 2.2 Biology & Function Of The BET Protein Family
- 2.3 BET Proteins As Therapeutic Targets
- 2.4 Emergence Of BRD4 As A Lead BET Target
- 2.5 Historical Development Of BRD4-Targeted Therapies

3. BIOLOGICAL RATIONALE FOR TARGETING BRD4

- 3.1 Structure & Domain Organization Of BRD4
- 3.2 Biological Functions Of BRD4
- 3.3 Role Of BRD4 In Gene Regulation
- 3.4 Role Of BRD4 In Cancer Hallmarks

4. THERAPEUTIC APPROACHES TARGETING BRD4

- 4.1 Small-Molecule BRD4/BET Inhibitors
 - 4.1.1 First-Generation BET Inhibitors
 - 4.1.2 Next-Generation & Selective BET Inhibitors
- 4.2 BRD4 Protein Degradation Approaches
 - 4.2.1 PROTAC-Based BRD4 Degraders
 - 4.2.2 Molecular Glue Degraders
- 4.3 Gene Silencing Strategies
 - 4.3.1 RNA-Based Gene Silencing
 - 4.3.2 CRISPR-Based BRD4 Targeting
- 4.4 Drug Repurposing Strategies
- 4.5 Emerging BRD4-Targeting Strategies
 - 4.5.1 Covalent & Allosteric BRD4 Inhibitors
 - 4.5.2 Dual-Target BRD4 Therapeutics

5. DISEASE BIOLOGY & THERAPEUTIC RATIONALE

- 5.1 BRD4 in Cancer
 - 5.1.1 Hematological Malignancies

- 5.1.2 Solid Tumors
- 5.2 Non-Oncology Opportunities
 - 5.2.1 Autoimmune & Inflammatory Diseases
 - 5.2.2 Microbial Infections
 - 5.2.3 Cardiovascular Diseases

6. BRD4 TARGETED THERAPIES COMBINATION THERAPEUTIC APPROACHES

- 6.1 BRD4 Targeted Therapies With Epigenetic Drugs
- 6.2 BRD4 Targeted Therapies With Tyrosine Kinase Inhibitors
- 6.3 BRD4 Targeted Therapies With BCL-2 Inhibitors
- 6.4 BRD4 Targeted Therapies With Photodynamic Therapy

7. GLOBAL BRD4 TARGETED THERAPIES CLINICAL TRIALS OVERVIEW

- 7.1 By Phase
- 7.2 By Country
- 7.3 By Company
- 7.4 By Indication
- 7.5 By Priority Status

8. GLOBAL BRD4 TARGETED THERAPIES CLINICAL TRIALS BY COMPANY, INDICATION & PHASE

- 8.1 Research
- 8.2 Preclinical
- 8.3 Phase-I
- 8.4 Phase-I/II
- 8.5 Phase-II
- 8.6 Phase-III

9. BRD4 TARGETED THERAPIES DEVELOPMENT PLATFORMS

10. GLOBAL BRD4 TARGETED THERAPIES MARKET TREND & DEVELOPMENTS

- 10.1 Current Market Outline
- 10.2 Future Development Directions

11. GLOBAL BRD4 TARGETED THERAPIES MARKET DYNAMICS

11.1 Market Drivers & Opportunities

11.2 Market Challenges & Restraints

12. COMPETITIVE LANDSCAPE

12.1 DeepCure

12.2 Epigenetix

12.3 Inhalis Therapeutics

12.4 Kainos Medicines

12.5 Mitsubishi Tanabe Pharma Corporation

12.6 Model Medicines

12.7 Opna Bio

12.8 Plexium

12.9 Prazer Therapeutics

12.10 Ranok Therapeutics

List Of Tables

LIST OF TABLES

Table 2-1: Classification Of Epigenetic Regulators

Table 2-2: BET Family Members & Tissue Distribution

Table 2-3: BET Proteins As Drug Targets - Advantages & Challenges

Table 2-4: Major Discoveries That Established BRD4 As The Lead BET Target

Table 3-1: BRD4-Mediated Gene Regulation Mechanisms

Table 3-2: Effect Of BRD4 Inhibition On Cancer Hallmarks

Table 4-1: First-Generation BET Inhibitors - Advantages & Limitations

Table 4-2: Comparison Of BET Inhibition Strategies

Table 4-3: PROTAC vs Molecular Glue: Structural & Pharmacological Comparison

Table 4-4: siRNA vs shRNA vs ASO vs miRNA: Functional Comparison

Table 4-5: BRD4 Drug Repurposing - Advantages & Limitations

Table 4-6: Dual BRD4 Therapeutics - Advantages & Challenges

Table 5-1: BRD4-Targeted Antimicrobial Therapy - Advantages & Challenges

Table 6-1: Representative BRD4–Photodynamic Therapy Strategies

Table 11-1: Global BRD4 Targeting Therapies Market –Challenges & Potential Solutions

List Of Figures

LIST OF FIGURES

Figure 2-1: Overview Of Epigenetic Regulation & Therapeutic Target Classes

Figure 2-2: Overview Of Epigenetic Machinery

Figure 2-3: Structural Organization Of BET Proteins

Figure 2-4: BET Protein-Mediated Recognition Of Histone Acetylation - Mechanism

Figure 2-5: BET-Dependent Transcriptional Addiction In Cancer

Figure 2-6: Cancers Associated With BRD4 Dysregulation

Figure 2-7: BRD4 Therapeutic Strategies - Evolution

Figure 2-8: BRD4-Targeted Therapy Development - Historical Timeline

Figure 3-1: BRD4 Protein - Functional Architecture

Figure 3-2: BRD4 - Integrator Of Multiple Cellular Pathways

Figure 3-3: BRD4 - Major Biological Functions

Figure 3-4: BRD4 Coordinates Multiple Levels Of Gene Regulation

Figure 3-5: BRD4 In The Hallmarks Of Cancer

Figure 4-1: First-Generation BET Inhibitors - Mechanism & Limitations

Figure 4-2: Representative First-Generation BET Inhibitors

Figure 4-3: Evolution Towards Selective BET Inhibitors

Figure 4-4: BRD4 Degradation Via PROTAC

Figure 4-5: BRD4 PROTAC Degradators - Advantages

Figure 4-6: Molecular Glue-Mediated BRD4 Degradation - Mechanism

Figure 4-7: Molecular Glue Degradators For BRD4 Therapy - Advantages

Figure 4-8: CRISPRi vs CRISPRa: Bidirectional Control Of BRD4 Expression

Figure 4-9: CRISPR Technologies For BRD4 Research - Evolution

Figure 4-10: Challenges Limiting Clinical Translation of BRD4 CRISPR Therapy

Figure 4-11: Drug Repurposing Strategies For BRD4 Targeting - Overview

Figure 4-12: Next-Generation BRD4-Selective Inhibitors

Figure 4-13: Covalent BRD4 Inhibition - Mechanism

Figure 4-14: Canonical vs Non-Canonical BRD4 Binding

Figure 4-15: Allosteric BRD4 Inhibition - Mechanism

Figure 4-16: Next-Generation BRD4 Inhibitor Development - Challenges

Figure 4-17: Dual-Target BRD4 Therapeutics - Concept

Figure 5-1: CHAMP-1 Phase 1/2 (NCT05487170) Study – Initiation & Completion Year

Figure 5-2: CA011-023 Phase 1/2 (NCT04817007) Study – Initiation & Completion Year

Figure 5-3: NCI-2022-04100 Phase 1 (NCT05372640) Study – Initiation & Completion Year

Figure 5-4: NCI-2020-04495 Phase 1 (NCT04471974) Study – Initiation & Completion Year

Figure 5-5: NCI-2023-03408 Phase 1 (NCT05950464) Study – Initiation & Completion Year

Figure 5-6: HLD-0915-ONC-101 Phase 1/2 (NCT06800313) Study – Initiation & Completion Year

Figure 5-7: Autoimmune & Inflammatory Diseases - Therapeutic Applications Of BRD4 Inhibition

Figure 5-8: BRD4 As A Host-Directed Therapeutic Target In Microbial Infections

Figure 5-9: BRD4 As A Central Regulator Of Cardiovascular Diseases

Figure 6-1: Rationale For Combining BRD4 Inhibitors With Epigenetic Therapies

Figure 6-2: BRD4-TKIs Combination Therapy - Rationale

Figure 6-3: BRD4-BCL-2 Combination Therapy - Rationale

Figure 6-4: BRD4 Inhibition & Photodynamic Therapy Combination - Biological Effects

Figure 7-1: Global – Number Of BRD4 Targeted Therapies In Clinical Trials By Phase, 2026

Figure 7 -2: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Country, 2026

Figure 7-3: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Company, 2026

Figure 7-4: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Indication, 2026

Figure 7-5: Global – Number Of BRD4 Targeted Therapies Clinical Trials By Priority Status, 2026

Figure 9-1: Vyne Therapeutics - BET Inhibitor Platform

Figure 10-1: BRD4-Targeted Therapeutics - Future Opportunities

Figure 11-1: Global BRD4 Targeting Therapies Market – Favorable Parameters

I would like to order

Product name: BRD4 Targeted Therapies Market Opportunity, Technology Platform, Development Trends & Clinical Trials Insights 2026

Product link: <https://marketpublishers.com/r/BDC6EBCA146CEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BDC6EBCA146CEN.html>